Milrinone

Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents

Posted on by Kayla Korzekwinski

Journal of Clinical Pharmacology • December 2019

Access article on PubMed.

Hornik CP, Yogev R, Mourani PM, Watt KM, Sullivan JE, Atz AM, Speicher D, Al-Uzri A, Adu-Darko M, Payne E, Gelber C, Lin S, Harper B, Melloni C, Cohen-Wolkowiez M, Gonzalez D

Milrinone is a type 3 phosphodiesterase inhibitor used to improve cardiac output in critically ill infants and children. Milrinone is primarily excreted unchanged in the urine, raising concerns for toxic accumulation in the setting of renal dysfunction of critical illness. We developed a population pharmacokinetic model of milrinone using nonlinear mixed-effects modeling in NONMEM to perform dose-exposure simulations in children with variable renal function. Children below 21 years of age were included.

Safety of milrinone use in neonatal intensive care units

Posted on by Kayla Korzekwinski

Early Human Development • January 2015

Access article on PubMed.

Samiee-Zafarghandy S, Raman SR, van den Anker JN, McHutchison K, Hornik CP, Clark RH, Smith PB; Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee.

Milrinone use in the neonatal intensive care unit has increased over the last 10 years despite a paucity of published safety data in infants. We sought to determine the safety of milrinone therapy among infants in the neonatal intensive care unit. We conducted a retrospective data analysis, identifying all infants who were exposed to milrinone and discharged from 322 neonatal intensive care units managed by the Pediatrix Medical Group from 1997-2010.